Literature DB >> 12518185

Angiotensin receptors in the cardiovascular system.

Lodewijk J Wagenaar1, Adriaan A Voors, Hendrik Buikema, Wiek H van Gilst.   

Abstract

The angiotensin II receptors mediate the effects of the renin-angiotensin system, which has an important role in cardiovascular (patho)physiology. Four types of angiotensin receptors are known, of which the type 1 (AT1) and the type 2 (AT2) receptors are the most important. Stimulation of the AT1 receptor leads to a cascade of signalling pathways in several cell types, which finally leads to processes such as vasoconstriction, inflammation and proliferation. These processes are of great importance in various cardiovascular diseases, including hypertension, atherosclerosis and ventricular hypertrophy. The AT2 receptor is expressed mainly in the fetal stage. In adults, the AT2 receptor is minimally expressed under normal circumstances. Its role in the adult cardiovascular system is not well established, but its effects seem to oppose those of the AT1 receptor. This overview discusses the pathophysiological role of the angiotensin II receptors in various cardiovascular diseases with the emphasis on the signal transduction of the AT1 and the AT2 receptors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12518185

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  11 in total

1.  Catalog of 178 variations in the Japanese population among eight human genes encoding G protein-coupled receptors (GPCRs).

Authors:  Susumu Saito; Aritoshi Iida; Akihiro Sekine; Saori Kawauchi; Shoko Higuchi; Chie Ogawa; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2003-08-30       Impact factor: 3.172

2.  Angiotensin II induces the aggregation of native and oxidized low-density lipoprotein.

Authors:  Akira Sato; Chiemi Ueda; Ryu Kimura; Chisato Kobayashi; Yoji Yamazaki; Keiichi Ebina
Journal:  Eur Biophys J       Date:  2017-04-11       Impact factor: 1.733

3.  Estrogen receptor-beta prevents cardiac fibrosis.

Authors:  Ali Pedram; Mahnaz Razandi; Fiona O'Mahony; Dennis Lubahn; Ellis R Levin
Journal:  Mol Endocrinol       Date:  2010-09-01

4.  Estrogen inhibits cardiomyocyte hypertrophy in vitro. Antagonism of calcineurin-related hypertrophy through induction of MCIP1.

Authors:  Ali Pedram; Mahnaz Razandi; Mark Aitkenhead; Ellis R Levin
Journal:  J Biol Chem       Date:  2005-05-16       Impact factor: 5.157

5.  Estrogen inhibits cardiac hypertrophy: role of estrogen receptor-beta to inhibit calcineurin.

Authors:  Ali Pedram; Mahnaz Razandi; Dennis Lubahn; Jinghua Liu; Mani Vannan; Ellis R Levin
Journal:  Endocrinology       Date:  2008-03-27       Impact factor: 4.736

Review 6.  Pleiotropic effects of angiotensin receptor blockers: addressing comorbidities by optimizing hypertension therapy.

Authors:  Peter P Toth
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-10-05       Impact factor: 3.738

Review 7.  Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.

Authors:  Suzan Willemsen; Jasper W L Hartog; M Rebecca Heiner-Fokkema; Dirk J van Veldhuisen; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

8.  Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.

Authors:  Ali Pedram; Mahnaz Razandi; Ramesh Narayanan; James T Dalton; Timothy A McKinsey; Ellis R Levin
Journal:  Mol Biol Cell       Date:  2013-10-23       Impact factor: 4.138

Review 9.  Results of the ONTARGET and TRANSCEND studies: an update and discussion.

Authors:  David Fitchett
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

Review 10.  Clinical trial update: focus on the ONTARGET study.

Authors:  David Fitchett
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.